Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response

Am J Hematol. 1998 Sep;59(1):95-7. doi: 10.1002/(sici)1096-8652(199809)59:1<95::aid-ajh19>3.0.co;2-0.

Abstract

A patient with chronic myeloid leukemia (CML) treated with interferon alpha (IFN alpha) and who developed autoimmune hepatitis (AIH) is described. The patient was treated with IFN alpha 2a, a complete cytogenetic response was achieved 5 months later, and this response has lasted now more than 7 years. Autoimmune hypothyroidism appeared at 18 months of treatment, and 1 year later severe type I autoimmune hepatitis developed. To our knowledge this is the first report of such complication in an IFN alpha-treated CML patient.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases / etiology*
  • Blotting, Southern
  • Female
  • Hepatitis / etiology*
  • Hepatitis / immunology*
  • Humans
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use*
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Middle Aged
  • Severity of Illness Index

Substances

  • Interferon-alpha